top of page

Theragnostic Technologies Receives Phase 1 SBIR Grant from National Institute of Health (NIH)

ManGraDex at Stony Brook Exhibited at Stony Brook's Second Annual Incubator Showcase

ManGraDex Graphene-Based MRI Contrast Agent Featured in Graphene Investor

Published in Nature Reports: Theragnostic Technologies Non-Gadolinium Based MRI Contrast Agent

Theragnostic Tech Introduces ManGraDex at TechConnect Accelerator Showcase

Theragnostic Technologies will be introducing ManGraDex MRI technology at the TechConnect Innovation Showcase and Accelerator program, the World’s largest showcase and accelerator for industry-vetted emerging-technologies ready for commercialization. We are seeking to connect with investors and development partners.

Read Full Press Release

bottom of page

Recent Posts

Theragnostic Tech Introduces ManGraDex at TechConnect Accelerator Showcase